Amalgamated Bank Has $1.73 Million Stock Position in Natera, Inc. $NTRA

Amalgamated Bank lifted its stake in shares of Natera, Inc. (NASDAQ:NTRA) by 23.8% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 10,263 shares of the medical research company’s stock after buying an additional 1,970 shares during the period. Amalgamated Bank’s holdings in Natera were worth $1,734,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of NTRA. Bank of Jackson Hole Trust acquired a new position in shares of Natera during the first quarter worth $29,000. TCTC Holdings LLC increased its holdings in shares of Natera by 114.8% during the first quarter. TCTC Holdings LLC now owns 232 shares of the medical research company’s stock worth $33,000 after buying an additional 124 shares in the last quarter. Northwestern Mutual Wealth Management Co. increased its holdings in shares of Natera by 83.5% during the first quarter. Northwestern Mutual Wealth Management Co. now owns 233 shares of the medical research company’s stock worth $33,000 after buying an additional 106 shares in the last quarter. Hilltop National Bank acquired a new position in shares of Natera during the second quarter worth $33,000. Finally, Oliver Lagore Vanvalin Investment Group acquired a new position in shares of Natera during the second quarter worth $36,000. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Natera Price Performance

NTRA stock opened at $199.92 on Thursday. The stock has a market capitalization of $27.44 billion, a PE ratio of -104.67 and a beta of 1.75. The company’s 50-day moving average is $176.51 and its 200-day moving average is $163.03. Natera, Inc. has a 1 year low of $123.61 and a 1 year high of $203.23.

Natera (NASDAQ:NTRA) last released its quarterly earnings data on Thursday, August 7th. The medical research company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.14). The company had revenue of $546.60 million for the quarter, compared to the consensus estimate of $476.84 million. Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.Natera’s revenue for the quarter was up 32.2% compared to the same quarter last year. During the same period last year, the company earned ($0.30) EPS. On average, analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Insider Buying and Selling at Natera

In related news, insider Solomon Moshkevich sold 3,000 shares of the company’s stock in a transaction dated Monday, November 3rd. The shares were sold at an average price of $198.60, for a total value of $595,800.00. Following the sale, the insider owned 112,061 shares in the company, valued at $22,255,314.60. This represents a 2.61% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Steven Leonard Chapman sold 160,703 shares of the company’s stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $199.96, for a total transaction of $32,134,171.88. Following the completion of the sale, the chief executive officer owned 144,816 shares in the company, valued at $28,957,407.36. This represents a 52.60% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 224,889 shares of company stock worth $43,232,062. 5.63% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

NTRA has been the topic of several analyst reports. Piper Sandler reissued an “overweight” rating and issued a $220.00 price objective (up previously from $210.00) on shares of Natera in a research note on Monday, August 11th. BTIG Research boosted their price objective on shares of Natera from $200.00 to $210.00 and gave the stock a “buy” rating in a research note on Thursday, October 23rd. Zacks Research cut shares of Natera from a “hold” rating to a “strong sell” rating in a research note on Monday, October 20th. Stephens reissued an “overweight” rating and issued a $183.00 price objective on shares of Natera in a research note on Friday, August 15th. Finally, Morgan Stanley reissued an “overweight” rating and issued a $195.00 price objective on shares of Natera in a research note on Sunday, August 10th. One analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $194.89.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.